Witryna18 gru 2014 · The IMPROVE-IT trial provides the first evidence from a large-scale event-driven randomized clinical trial that additional lipid modifying therapy further lowering LDL-C provides further CVD event reduction beyond statin … Witryna18 cze 2015 · When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit. (Funded by Merck; IMPROVE-IT ClinicalTrials.gov number, NCT0020287 …
Improvement Summary SuperSummary
WitrynaVytorin Efficacy International Trial (IMPROVE-IT) evaluated the effect of ezetimibe combined with simvastatin, as compared with that of simva-statin alone, in stable … WitrynaOther trials have shown that digital adherence technologies (SMS-based and those based on medication event reminder monitors), implemented in real-time, can improve successful treatment outcomes. It is important, though, to understand the cost of delivering such interventions and also how these can be implemented in routine practice. chicago majority race
Ezetimibe and Improving Cardiovascular Outcomes: Current ... - Hindawi
WitrynaThe results of the IMPROVE-IT trial are fostering new debate about the value of adjunctive low-density lipoprotein cholesterol lowering over and above a statin. Summary Ezetimibe / simvastatin combination, either as a single pill or as the combined use of the individual compounds, represents a well-tolerated and efficacious choice for ... Witryna1 lis 2008 · The IMPROVE-IT trial has become even more important since the release of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial results, 24 which compared the effects the combination of ezetimibe and high-dose simvastatin with high-dose simvastatin alone on carotid … Witryna5 godz. temu · This article summaries discussions involving academia, the pharmaceutical industry, patient groups, and government agencies held during a 2024 US Food and Drug Administration (FDA) workshop to improve the regulatory and clinical trial infrastructure necessary to develop antifungals for invasive fungal infections. google drive plug in for office